What exactly did Barclays change for Vir on Feb 24 2026?

Barclays maintained an **Overweight** rating on Vir Biotechnology, Inc. on **Feb 24, 2026**, and raised the price target to **$30** from **$26**. The move lifts fair‑value expectations without altering the core rating.

How should investors interpret the VIR analyst rating maintenance?

A maintained **VIR analyst rating** of Overweight suggests expected outperformance versus peers. Investors should see the raise in target as incremental confidence, not a full endorsement for immediate buying.

Does Barclays’ price target change affect Vir’s valuation?

Yes. Barclays’ move to **$30** increases one major sell‑side fair value input. It shifts analyst target averages higher but does not guarantee stock appreciation.

What is Meyka AI’s current grade for VIR and what it means?

Meyka AI rates VIR with a grade of **B**. This factors in S&P 500 comparison, sector performance, growth, metrics, and analyst consensus. Grades are informational, not investment advice.

Analyst Ratings

Barclays Maintains Overweight on Vir Biotechnology, Inc. (VIR) Feb 24 2026

ByDanny Kontos February 25, 2026February 25, 2026

Barclays maintained Overweight on Vir Biotechnology, Inc. (VIR) and raised its price target to $30 on Feb 24, 2026, marking the main change in this update. The VIR analyst rating update combines the retained positive view with a modest target lift from $26. The move signals Barclays expects stronger midterm value from VIR’s pipeline progress. We use Meyka AI’s coverage to place the call in market context and outline investor implications.